Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

e potential to significantly enhance the efficacy of oncolytic virotherapy. About a third of those patients also showed increases in NK (natural killer) cells following therapy. The data support the development of interventions aimed at blunting the patient's immune response, although preclinical data also suggest that maintaining a baseline level is necessary to restrict systemic spread and toxicity of the virus.

Manufacturing and Process Development

In the first quarter of 2008, after completing the technology transfer of our 40-litre production process to our manufacturer in the U.S., we commenced production at the 40-litre scale under cGMP conditions for use in our clinical trials. Our process development activity continued to focus on scale up from 40-litre to 100-litre production runs.

Intellectual Property

During the first quarter of 2008, one U.S. and two Canadian patents were issued. At the end of the first quarter of 2008, we had been issued over 170 patents including 26 U.S. and eight Canadian patents as well as issuances in other jurisdictions. We also have over 180 patent applications filed in the U.S., Canada and other jurisdictions.

Financial Impact

We estimated at the beginning of 2008 that our average monthly cash usage would be approximately $1,660,000 for 2008. Our cash usage for the first quarter of 2008 was $2,991,234 from operating activities and $259,969 for the purchases of intellectual property and capital assets which is lower than our expected monthly average but is in line with our expectations for 2008. Our net loss for the first quarter of 2007 was $3,324,241.

Cash Resources

We exited the first quarter of 2008 with cash resources totaling $21,962,626 (see "Liquidity and Capital Resources").

Expected REOLYSIN(R) Development for the Remainder of 2008

We plan to continue to enroll patients in our clinical trials throughout 2008 and still expect to complete enrollment in
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014 Appistry, Inc. , a ... the power of genomics to next-generation medicine, announced today ... Challenge . , Two Appistry staff will be ... Center for Genome Resources, and Mr. Neil Miller, director ... Kansas City. Rounding out the panel are Appistry’s Dr. ...
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014 /PRNewswire/ ... will be a 177-key, 4-star boutique hotel in the heart ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... the first hotel within ATLAS , The ... mixture of standard rooms and suites, a sleek restaurant and bar, ...
(Date:7/25/2014)... "Ischemic Stroke and Cerebral Stroke ... on the Ischemic Stroke and Cerebral Stroke clinical ... data relating to the clinical trials on Ischemic ... Ischemic Stroke Research Report 2014 at: http://www.marketresearchreports.biz/analysis/213207 ... trial numbers and their recruitment status as per ...
(Date:7/25/2014)... -- Research and Markets  has announced the ... report to their offering. ... Metabonomics is the scientific study of chemical processes ... technique that is being widely used in biology, ... molecules that are present in blood, urine, and ...
Breaking Biology Technology:Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... of Health, The Infectious Disease Research, Institute and ... of Advisors, SEATTLE, Oct. 7 The ... acquisition of compounds for further,development into tuberculosis (TB) ... SUMM) of Oxfordshire, UK, and the Microbial Chemistry,Research ...
... Oct. 7 BioEnergy International, LLC,(BioEnergy), a ... biochemicals and biofuels, announces the,addition of Norman ... effective December,2008. Mr. Augustine has a record ... level of industry and government culminating in ...
... Oct. 7 Morria Biopharmaceuticals Plc, ... of novel,anti-inflammatory drugs, announced today the ... novel anti-inflammatory drugs using MD Biosciences,Immunoprofiler(TM) ... was specifically,chosen to identify and assess ...
Cached Biology Technology:Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 2Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 3Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 4Update: The Lilly TB Drug Discovery Initiative Begins Work on New Compounds to Fill Early-Stage TB Drug Pipeline 5BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 2BioEnergy International, LLC Announces Norman R. Augustine to Join Advisory Board 3Morria Biopharmaceuticals Plc Announces Results From its Pre-Clinical Screening of Novel Anti-Inflammatory Compounds 2
(Date:7/28/2014)... CITY (July 28, 2014)The Brain & Behavior Research ... Klerman and Freedman Prizes, recognizing exceptional clinical and ... supported by NARSAD Young Investigator Grants. The grants ... in neurobiological and psychosocial research for the prevention, ... that affect one in four people. , Six ...
(Date:7/28/2014)... Research and Markets has announced ... America 2014-2018" report to their offering. ... and analyze biological data. These systems capture biological traits ... patterns, and hand measurements from the subject and compare ... main purpose of a biometrics system is to identify ...
(Date:7/28/2014)... from fertility problems, many of these due to genetic ... expect such genes, which reduce an individual,s ability to ... Weizmann Institute of Science that recently appeared in ... Not only can it explain the high rates of ... understanding the causes of genetic diseases and their treatment. ...
Breaking Biology News(10 mins):The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 2The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 3The Brain & Behavior Research Foundation names winners of Klerman and Freedman Prizes 4Biometrics Market in Latin America 2014-2018 2Mutations from Venus, mutations from Mars 2
... has evolved a unique technique for sensing motion may inspire ... active sonar. Although members of the fish ... environment and the movement of water around them with gel-covered ... underwater objects and navigate through their lightless environment inspired a ...
... a traffic accident with personal injury is significantly higher ... use of codeine alone does not carry an increased ... Norwegian Institute of Public Health. Codeine and ... mild to moderate pain. In Norway, codeine is included ...
... 2009 / b3c newswire / -  LabRoots Inc. ... social networking site for the scientific community. Beginning today, ... to LabRoots.com to begin building relationships with other scientists ... from giving scientists a place to share their expertise ...
Cached Biology News:Researchers develop flow sensors based on hair structures of blind cavefish 2Researchers develop flow sensors based on hair structures of blind cavefish 3Codeine use and accident risk 2LabRoots Launches Social Networking Site for Scientists & Engineers 2
... Systems provide fast and reliable automation ... and drug development laboratories. Staccato Custom ... specifications, providing solutions that are tailored ... Custom Systems are controlled with either ...
... Not treated (or medium binding) polystyrene ... binds biomolecules through passive interactions,• Is ... large molecules, such as antibodies, that ... interact with the surface,• Binding capacity ...
... tabs • Reusable, press-to-seal gasket and ... assembled and disassembled for hybridizing and imaging ... thickness with up to a 13 mm ... slide. Minimize specimen handling, eliminate evaporation and ...
...
Biology Products: